Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in April

Vor Biopharma Inc. (NASDAQ:VOR) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 4,706,707 shares, a drop of 17.3% from the March 31st total of 5,687,983 shares. Based on an average trading volume of 1,347,900 shares, the short-interest ratio is currently 3.5 days. Approximately 9.7% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

VOR has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. HC Wainwright dropped their price objective on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Wall Street Zen raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. Wedbush lifted their price objective on Vor Biopharma to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Vor Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $50.56.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $14.33 on Friday. The stock has a fifty day moving average of $14.98 and a 200 day moving average of $15.14. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The firm has a market capitalization of $776.54 million, a price-to-earnings ratio of -0.04 and a beta of 1.92.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director directly owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. This trade represents a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 3,002,903 shares of company stock valued at $49,412,176 over the last three months. 0.45% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently added to or reduced their stakes in VOR. China Universal Asset Management Co. Ltd. purchased a new stake in Vor Biopharma during the fourth quarter valued at about $36,000. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma during the second quarter valued at about $66,000. Chung Wu Investment Group LLC purchased a new stake in Vor Biopharma during the fourth quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma during the fourth quarter valued at about $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).